3,071 Shares of Illumina, Inc. $ILMN Purchased by Curated Wealth Partners LLC

Curated Wealth Partners LLC bought a new position in Illumina, Inc. (NASDAQ:ILMN) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,071 shares of the life sciences company’s stock, valued at approximately $840,000.

A number of other hedge funds also recently made changes to their positions in ILMN. Fiduciary Financial Advisors purchased a new stake in shares of Illumina during the 2nd quarter worth approximately $26,000. MCF Advisors LLC boosted its position in shares of Illumina by 172.4% during the 2nd quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 100 shares during the last quarter. Keating Financial Advisory Services Inc. purchased a new position in shares of Illumina in the second quarter valued at $32,000. Rakuten Securities Inc. purchased a new position in shares of Illumina in the second quarter valued at $33,000. Finally, WealthCollab LLC grew its holdings in shares of Illumina by 51.5% in the first quarter. WealthCollab LLC now owns 303 shares of the life sciences company’s stock valued at $37,000 after purchasing an additional 103 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, SVP Christensen Wedel sold 1,033 shares of Illumina stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the transaction, the senior vice president directly owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith Meister sold 119,501 shares of Illumina stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the transaction, the director directly owned 770,350 shares of the company’s stock, valued at approximately $168,244,440. This represents a 13.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 2,061,850 shares of company stock valued at $436,479,102 in the last 90 days. Company insiders own 2.90% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Canaccord Genuity Group boosted their price target on shares of Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a research report on Monday, August 3rd. UBS Group upgraded shares of Illumina from a “neutral” rating to a “buy” rating and increased their price objective for the company from $135.00 to $260.00 in a research report on Wednesday, September 9th. Zacks Research lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 1st. Guggenheim lifted their price objective on shares of Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Finally, Deutsche Bank Aktiengesellschaft cut shares of Illumina to a “hold” rating in a research note on Wednesday, August 5th. Ten investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $225.94.

Illumina Stock Down 1.4%

Shares of ILMN opened at $267.93 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The business has a fifty day moving average of $233.03 and a 200 day moving average of $185.47. The company has a market cap of $40.46 billion, a PE ratio of 52.77, a P/E/G ratio of 3.85 and a beta of 1.41. Illumina, Inc. has a 52-week low of $93.50 and a 52-week high of $309.35.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter in the previous year, the business posted $1.19 earnings per share. The business’s revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, sell-side analysts expect that Illumina, Inc. will post 5.36 EPS for the current year.

About Illumina

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.